Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Tonix Pharmaceuticals Holding Corp. (TNXP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.5053-0.0225 (-4.26%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5278
Open0.5335
Bid0.5020 x 800
Ask0.5026 x 800
Day's Range0.5007 - 0.5343
52 Week Range0.4600 - 2.1200
Volume15,272,108
Avg. Volume14,994,901
Market Cap167.022M
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-0.3960
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.75
  • Motley Fool

    Why Tonix Pharmaceuticals Is Up by 6% Today

    Tonix Pharmaceuticals (NASDAQ: TNXP), a rather up-and-down meme stock in the biotech sector, was having a fine day on the market Tuesday. Tuesday morning, Tonix was all too happy to announce that the Food and Drug Administration (FDA) has cleared the Investigational New Drug application for its TNX-1900. The treatment of migraines has been a thorny challenge for biotechs and pharmaceutical companies for many years.

  • GlobeNewswire

    Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs

    Approximately Four Million in U.S. Suffer from Chronic Migraine Development of TNX-1900 Also Planned for Treatment of Episodic Migraine, Craniofacial Pain and Insulin Resistance CHATHAM, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) Application to support the initiation of a Phas

  • GlobeNewswire

    Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight

    Early Studies in vitro Show that TNX-3500 is a Potent Antiviral Against Multiple Variants of SARS-CoV-2, the Cause of COVID-19, and Potentiates RemdesivirCHATHAM, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of “Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties,” in JCI Insight. The paper includes in vitro s

Advertisement
Advertisement